Avanos Medical Q2 net sales rise 1.9%, beat expectations

Overview

• Avanos Q2 2025 net sales rise 1.9%, beating analyst expectations, per LSEG data

• Net loss of $76.8 mln due to $77.0 mln goodwill impairment charge

• Adjusted EPS for Q2 was $0.17, down from $0.34 last year

• Co maintains 2025 revenue guidance of $665 mln to $685 mln

Outlook

• Avanos maintains 2025 revenue guidance of $665 mln to $685 mln

• Company expects 2025 adjusted EPS between $0.75 and $0.95

• Guidance includes impact of HA divestiture

• Company cites tariff impact as a risk to financial results

Result Drivers

• SPECIALTY NUTRITION - Strong demand in SNS segment drove 1.9% sales increase

• RFA SALES - Growth in radiofrequency ablation generator sales boosted procedure volume

• SURGICAL PAIN DECLINE - Lower volume in surgical pain and recovery portfolio impacted overall performance

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "hold"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

• The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: